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Summary Metastatic renal cell carcinoma (RCC) has a poor prognosis. Conventional treatment strategies, including chemotherapy and
hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological
manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was
undertaken, which compared one of the present (and presumed best) treatments, interleukin 2/interferon-a (IL-2/IFN-a) and tamoxifen, with
a control arm of tamoxifen only. Tamoxifen has been shown to potentiate in vivo anti-tumour activity of IL-2, and because of its non-toxic
behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The patients were
stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 patients were evaluable. The
128 patients finally included had a histologically documented metastatic RCC, with a life expectancy of more than 3 months, a performance
status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each patient. The patients randomized to the
control arm (n = 63) received only tamoxifen 40 mg p.o. daily for at least 1 year or until progression. The patients (n = 65) randomized to
biotherapy received subcutaneous recombinant IL-2, leucocyte IFN-a in a treatment cycle of 42 days, as well as tamoxifen p.o. In the
absence of undue toxicity or disease progression, these patients received one additional treatment cycle of 42 days followed by maintenance
treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two patients in the tamoxifen-only group
received immunotherapy when the disease progressed, but without any beneficial effect. All patients received appropriate local treatment
when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of patients was
stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between
the two treatment arms in so far as comparison from the day of diagnosis of primary disease, from the day of first evidence of metastatic
spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the
analysis was directed only to patients that managed at least one treatment cycle (42 days) of IL-2/IFN-a. The adverse effects were more
pronounced in the IL-2/IFN-a group. Although the number of patients is limited, the results raise doubt concerning immunotherapy with IL-2
and IFN-a as a routine treatment in the management of advanced RCC. The difference in cost of drugs and health care (drug costs per
patient: IL-2/IFN-a $27000 vs tamoxifen $360) as well as adverse effects caused by IL-2/IFN-a are also factors of importance. The study
emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies
before approval of a new treatment in the routine setting.
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Advanced renal cell carcinoma (RCC) is considered to be beyond
curative treatment. Chemotherapy and radiotherapy are only used
in thepalliativesetting, andchemotherapy alone is oflimited value
(Oliver, 1994; Savage, 1995; Wagstaff et al, 1995). Hormonal
manipulation, such as medroxyprogesteron acetate and tamoxifen
have, in some observations, caused objective responses of short
duration (Harris, 1983; Linehan etal, 1989). RCC is one ofthe few
tumours with a known propensity for spontaneousregression (Katz
et al, 1982; Oliver et al, 1989). Host factors such as the immune
system may, in certain circumstances, influence the outcome. A
number of studies strongly suggest that interferon a(IFN-a) and
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interleukin 2 (IL-2), especially in combination, could be of thera-
peutic value (Rosenberg et al, 1993; Oliver, 1994; Atzpodien et al,
1995; Facendola, 1995; Savage, 1995; Wagstaff et al, 1995;
Hanninen etal, 1996). Although these treatmentoptions can induce
objective responses, they are associated with significant side-
effects and considerable expense (Oliver, 1994; Facendola et al,
1995; Savage, 1995; Wagstaff et al, 1995). At present, no conclu-
sive studies exist that, in prospective controlled fashion, have eval-
uated the effects of immunological manipulations on survival in
patients with RCC (Ljungberg and Henriksson, 1997). Therefore,
this randomized, controlled study compared subcutaneously
administered leucocyte IFN-a and IL-2 with peroral tamoxifen,
with special emphasis on survival. Tamoxifen has been shown to
cause objective responses and to potentiate in vivo activity ofIL-2
(Kim et al, 1990; Stahl et al, 1991). Owing to its well-tolerated
behaviour, it was included in both treatment arms.
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Table I Inclusion and exclusion crteria for participation in the study
Inclusion criteria
1. Histologically documented evidence of advanced RCC.
2. No pror chemotherapy, immunotherapy or extensive radiotherapy in the last 4 weeks (6 weeks for nitrosoureas, mitomycin C)
3. Ambulatory performance status WHO scale < 2
4. Age 18-75 years, and life expectancy greater than 3 months
5. WBC .3500; platelets 2 100 000; haematocrit .30%
6. Serum bilirubin < 1.25 x and creatinine < 1.50 x upper limit of the institutional normal range
Exclusion criteria
1. Any of the above criteria are not met
2. A significant history or current evidence of a symptomatic cardiovascular disease (in questionable cases a stress test should be performed), haematopoietic,
pulmonary, hepatic or renal dysfunctions
3. Patients with phaeochromocytoma or glaucoma
4. Patients positive for HIV, hepatitis B surface antigen (HB.Ag) and/or presenting with chronic hepatitis
5. Evidence of serious active infectious requiring antibiotic therapy
6. Contraindications to use of pressor agents
7. Patients with major organ allografts (IL-2 may increase T-cell mediated rejection, immunosuppressive agents are likely to reduce efficacy of IL-2) or
autoimmune disease.
8. Patients with clinical evidence of CNS metastases
9. Patients who require or are likely to require corticosteroids for intercurrent disease during the active treatment with IL-2/IFN-a and/ortamoxifen
10. Patients with know seizure disorders or CNS disease
11. Pregnant or lactating women
12. Patients with second primary malignancies, concurrently
13. Patients who do not give their inform consent
MATERIAL AND METHODS
Study objectives
The primary objective of this study was to compare the effects of
subcutaneously administered IL-2, IFN-a and tamoxifen with
tamoxifen alone in terms of overall survival in patients with
advanced RCC.
Study design
The study was an open, randomized, multicentre study including
seven major institutions in Sweden and was performed between
1992 and 1995. Inclusion and exclusion criteria are outlined in
detail in Table 1.
Two hundred patients were originally planned to be included in
the study. It was estimated that it would provide a power of 70%
certainty to detect a difference at the 5% level in increasing mean
survival from 10 months to 22 months. The patients were stratified
according to the different centres involved. An interim analysis
was intended to be performed when a minimum of 100 patients
were evaluable. In the final analysis, a total of 128 patients were
included in the study. In all, 65 patients were treated with a combi-
nation ofIL-2, LFN-a and tamoxifen, and 63 patients with tamox-
ifen alone (for details, see Table 2). One patient in each group was
older than stated in the inclusion criteria (77 and 78 years old
respectively) and included by mistake. They were included in the
analysis.
Study drugs and treatment schedule
Patients were randomized to a combined treatment with recombi-
nant IL-2 (Proleukin, EuroCetus, Division of Chiron, Emeryville
CA, USA), natural leucocyte interferon-a (Interferon AlfaNative,
BioNative AB, Umea, Sweden) (Ahrdn et al, 1992) and tamoxifen
(Tamaxin, Orion-Pharma, Sweden) or to tamoxifen alone. All
patients were treated with tamoxifen 40 mg p.o. daily. Patients
allocated to the combination therapy were also treated with regu-
larly repeated treatment cycles, including both IL-2 and IFN-a
(Table 3) according to a schedule reported previously by
Atzpodien and colleagues (1990). The treatment was given on an
outpatient basis and the patients usually managed their own
injections. Concomitant treatment with corticosteroids was not
allowed.
Forty of the 65 patients in the immunotherapy group were esti-
mated to have received 75% or more of the planned total dose of
IL-2 and TFN-a. Five patients received less than 25% of the
planned total dose.
Clinical assessments and laboratory examinations
After all inclusion and exclusion criteria were fulfilled, a general
physical examination and routine test for determination ofhaema-
tological and biochemical parameters were performed before
enrolment, and then repeated during every new treatment cycle
throughout the study. When clinical evidence of disease progres-
sion was obtained, a thorough radiological examination was
performed. In the case of a clear clinical and radiological deterio-
ration, the treatment was interrupted.
Adverse reactions
Toxicity was graded according to the WHO criteria, i.e. it was
graded as mild (grade 1), moderate (grade 2), severe (grade 3) and
life threatening (grade 4). IL-2 and IFN-a were reduced by 50% in
patients when grade 3 or 4 toxicity was present (Table 4).
Relapse treatment
The treatment options in the relapse situation was left to the discre-
tion of each responsible physician, but it was recommended to use
modalities other than immunotherapy. As only two patients in the
tamoxifen only group received immunotherapy (IFN-a) because of
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Table 2 Patients' characteristics at the time of inclusion in the study
Tamoxifen
Total no of patients enrolled
Sex (male/female)
Age median (range)
Previous nephrectomy
Number of patients with metastasis
Multiple location
1-3 metastasis
Lung >5 metastasis
Lung
Liver
Bone
Lymphoid glands
Local relapse
Laboratory values (mean s.e.m.)
Hb
Platelets
WBC
Creatinin
Albumin
63
49/14
63 (32-78)
52
39
21
23
45
6
18
19
5
128 (2.7)
295 (18)
11 (4.3)
111 (3.8)
39 (0.8)
IL-2AIFN-attamoxifen
65
43/22
61 (43-77)
54
37
20
19
32
11
15
19
8
127 (2.6)
342 (20)
8.9 (1.2)
103 (3.4)
38 (0.7)
Table 3 Schedule of recombinant IL-2 (Proleukin) + IFN-a (Interferon Alfanative)
A complete course of treatment on the used protocol comprised 6 weeks of s.c. IL-2 followed
by 2-3 weeks' rest. Patients received s.c. IL-2 4.8 x 106 IU m-2 persingle dose given q 8 h on
days 1 and 22, and q 12 h on day 2 and 23, followed by 2.4 x 106 IU m-2 q 12 h on day 3-5,
8-12, 15-19, 24-26, 29-33 and 36-40
In addition, patients received IFN-a at 3 x 106 IU m-2 on days 3, 5, 24, 26 and at 6 x 106 IU m-2
on days 8, 10, 12, 15, 17, 19, 29, 31, 33, 36, 38 and 40
Maintenance treatment
Five days' therapy every 4 weeks up to 1 year or until disease progression or undue toxicity
Daily: IL-2 at 2.4 x 106 IU m-2 q 12 h
Day 1, 3 and 5: IFN-a 3 x 106 IU m-2
Table 4 Survival values - intention to treat
Tamoxifen IL-2/IFN-actamoxifen
From randomization 13.3 (0.4-25.7) (8.4-18.2) 11.8 (0.5-28.9) (8.5-15.2)
From diagnosis 27.8 (1.4-180.3) (10.8-44.8) 30.2 (2.1-195.0) (14.7-45.7)
From metastasis 22.6 (1.4-114.0) (13.5-31.6) 18.0 (1.2-154.5) (8.6-27.4)
Median, range and 95% confidence interval - no significant differences. Expressed in months.
progressive disease and both patients displayed continuous progres-
sive disease, these patients were included in the final analysis of
intention to treat. Three patients in the IL-2AIFN-a arm received a
furthercourse ofIFN-a and IL-2. Radiotherapy was givenmainly as
pain palliation in 16 patients in the tamoxifen group and in 14
patients in the IL-2/IFN-a tamoxifen group. One patient in each
group received chemotherapy without any obvious effect.
Ethics
The study conformed to the Helsinki/Tokyo Declaration, and was
approved by the Ethics Committees at the University Hospital,
Umea, Uppsala, Lund,Orebro and Karolinska Institute, Stockholm.
All patients were given verbal and written information about the
study, and informed consent was obtained from each patient.
Statistics
Statistical evaluation was performed in blinded fashion by an inde-
pendent statistician. To estimate the probability of survival, the
Kaplan-Meier method was used. Differences in survival between
the two groups were tested using the log-rank test.
RESULTS
Interim analysis
An interim analysis was initiated when 100 patients were evalu-
ated. The analysis was performed by two independent investiga-
tors (not involved in the study), who were directed to evaluate any
differences in the survival between the two treatment arms. As
there were no signs ofsurvival advantage, and it was not probable
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that a further inclusion ofpatients could display aclinically mean-
ingful difference, it was recommended that the study should be
interrupted. The differences in adverse reactions between the two
treatment arms were also ofimportance in this decision.
Final analysis
When it was decided to stop the recruitment of patients, 128
patients had been randomized and included. The medianfollow-up
time was 11 months from randomization (range 0.4-48 months).
Within the first month after inclusion in thestudy, twopatients had
died in each ofthe treatment groups.
The survival (mortality) curves displayed no signs of statisti-
cally significant differences between the two treatment schedules
(intention to treat), regardless of whether the analysis was
performed from theday ofrandomization, from theday ofprimary
diagnosis, orfrom theday offirst evidence ofmetastasis(Figure 1).
Nor were there any differences if only patients included in the
survival analysis had received at least one treatment cycle of IL-2
and IFN-a (Figure 1 A-C inlets). There were no significant differ-
ences in mean or median survival of the patients in the two arms
(Table4).Twenty-sixpatients in the IL-2/IFN armand 30patients in
thetamoxifen-only treated group were alive 1 yearafterinitiation of
the treatment. There were no significant differences in long-term
survival. However, the number of patients in this long follow-up
was limited (Figure 1). It must be emphasized that the response
evaluation was not of primary concem; however, we observed
complete and partial responders in both groups. Five complete
responders (CRs) were seen in the IL-2/IFN-a group. Two CRs
wereobviously seen in the tamoxifen only group. Ofthesepatients,
the time to verified progression was 20-48+ months in the tamox-
ifenonly group and 30-54+ months in theimmunotherapy group.
The toxicities observed in this trial were similar to those
expected from other trials. Virtually all patients in the IL-2/IFN-tx
tamoxifen group experienced some degree of a flu-like syndrome,
including malaise and fever. Overall, the toxicity was graded 0-2
according to the WHO toxicity scale in the majority of the
patients. However, grade 3-4 toxicity was seen in a substantial
amount of patients and was more common in the IL-2/IFN-a-
treated patients (Table 5).
DISCUSSION
Metastatic RCC has a poorprognosis with a5-year survival ofless
than 10%. With only slight or no efficacy with conventional
chemotherapy and hormonal therapy, immunological manipula-
tions have attracted major interest (Rosenberg et al, 1993; Besana
et al, 1994; Oliver, 1994; Atzpodien et al, 1995; Facendola et al,
1995; Savage, 1995; Wagstaff et al, 1995; Hanninen et al, 1996).
Recombinant cytokines, notably IL-2 and IFN-a, appear to have
had encouraging results, and have led to approval by several
national drug agencies in the management of RCC. However, in
these studies, only objective responses were evaluated and the
results compared with historic control patients (Savage, 1995).
Therefore, it is of interest that the present study, which was
focused on survival analysis, could not display any detectable
differences in overall survival between a combination of IL-2,
IFN-a and tamoxifen with only tamoxifen. The results are espe-
cially noteworthy when considering the adverse effects of the
treatment and thehigher expense ofthe combined treatment arm.
The results from the present study could be questioned because
of the relatively limited number of patients included in the final
analysis. Nevertheless, as outlined and interpreted by the investi-
gators responsible for the interim analysis, a statistically signifi-
cant survival difference between the treatments could not be
detected unless considerably more patients were included. A
drawback of many of the previously reported trials is the conclu-
sion that the response rate was superior to 'historic controls', even
although these trials were not randomized, and often did not use
case-matched controls. Such drawbacks were emphasized by
Philip and colleagues (1993) in a single-institution analysis of
patients referred to their institution, thus further proving the
importance for randomized trials with concurrent controls. It is
also well known thatpatients with skeletal and/or livermetastases,
as a group, respond less favourably than patients with, for
example, only lung and/or lymph node metastases. Therefore,
another altemative could have been to include only this latter
patient category in this study. This protocol, however, investigated
the general applicability ofthetherapy concept in the management
of performance status patients (WHO 0-2) with metastasized
RCC. This approach was facilitatedby the recruitmentofconsecu-
tive patients and the randomizeddesign ofthe study. In addition to
the observation that survival was similar in the twopatient groups,
even in respect to long-term survival, it is ofimportance toempha-
size that the survival was quite comparable with survival data
reported in previous studies of RCC patients treated with IL-
2/IFN. In fact, median survival in each of the treatment groups
(see Table4) is betterthan that seen in the Swedishregistry studies
ofadvanced RCC patients. Moreover, the median survival has also
been shown in other IL-2/IFN studies to be at the same level at 12
months (Facendola et al, 1995).
Factors that could affect the outcome for patients with
metastatic disease include time from initial diagnosis, weight loss
and the number of metastatic sites involved (Elson et al, 1988).
However, this evaluation of survival did not seem to be different,
regardless of the time frame of the analysis (from the date of
primary diagnosis or the start ofthe treatment or from the time of
first signs ofmetastatic spread). There was no obvious initial vari-
ation in laboratory parameters or metastatic spread of the disease
(see Table 2), which furtherreduces theriskofdifferences in prog-
nostic factors between the treatment groups. The use of natural
interferon-a decreases the likelihood of neutralizing antibodies
(Priimmer, 1993), and no antibodies against IFN-ain repeated and
continuous analysis throughout the study were detected.
Previously published studies have also suggested that
immunotherapy has no impact on survival (Steineck et al, 1990;
Wagstaffet al, 1995). In this context it is also ofinterest to empha-
size that controlled randomized trials evaluating different
approaches ofimmunotherapy on survival, forexample IL-2 vs IL-
2 plus lymphokine-activated killer cells or IFN-a vs IFN-a and
vinblastin, displayed no significant differences (Fossaet al, 1992;
Rosenberg et al, 1993; Kellokumpu-Lehtinen et al, 1995).
Furthermore, the advantage of an increased response rate after
immunological manipulation has not always been translated to a
better chance ofsurvival (Fossaet al, 1992; Facendola et al, 1995).
This could imply that all the survival curves and the supposed
effects ofimmunotherapy simply highlighted the natural history of
the disease. This was further highlighted by the fact that no differ-
ences could be seen in survival between IFN-ylb and placebo in a
randomized study including 197 patients (Elhilai et al, 1997).
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Figure 1 Kaplan-Meier survival. Time to death from (A) randomization, (B) day of prmary diagnosis and (C) day of first evidence of metastatic spread. Large
figures denote intention to treat and inlets include in the IL-2/IFN-a schedule only those patients that have received at least 42 days (one cycle) treatment.
IL-2/IFN-a; -- -, tamoxifen-only treatment
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Table 5 Number of patients who suffered from WHO grade 3-4 toxicity
during treatment
Tamoxifen IL-2/lFN-a/tamoxifen
Total number of patients enrolled 63 65
Fatigue 19 38
Anorexia 7 14
Nausea 5 14
Fever 0 8
Diarrhoea 2 5
Myalgia 14 12
Pulmonary 11 9
Infection 0 2
Cutaneous 0 1
Headache 0 2
Oral 1 1
CNS 2 1
Spontaneous remissions were also seen in the placebo arm, thus
underlining the variable natural history of metastatic RCC.
Substantial improvement was recently shown in response rate over
other regimens in patients with progressing RCC (Hanninen et al,
1996) who, in anon-randomized evaluation, underwent altemating
cycles of combination of immunotherapy (IL-2 and IFN-a) and
chemoimmunotherapy (5-fluorouracil and IL-2). Once again, in
this study the overall response rate (CR+PR) of 39% was not
directly related to long-lasting remissions. The beneficial effect of
chemoimmunotherapy (IL-2, IFN-a and 5-FU) was further
proposed in a small randomized study against tamoxifen
(Atzpodien et al, 1997). It is also ofinterest to recall that a survival
benefit was seen for patients treated with cimetidine plus auto-
lymphocyte therapy compared with cimetidine only (Osband et al,
1990). Similar results have been seen when RCC patients with
nodal disease were given adjuvant therapy (Sawczuk et al, 1997).
Immunological manipulation, even with the present subcuta-
neous regimen, is associated with toxicity, at least during the treat-
ment period. The toxicity seen was in accordance with earlier
reports. The present study also included a substantial number of
patients with grade 3 and 4 toxicity in the IL-2- and IFN-a-treated
patients. Thus, when discussing any beneficial effects, these
aspects must also be considered. In evaluation of toxicity of a
given treatment, it must also be considered that a local tumour
progression could explain a deterioration. The observed CNS and
lung toxicity in the tamoxifen group most probably were due to
local tumour growth.
Hormone manipulation has been used for the treatment ofRCC
for many years. The initial high response rate of medroxyproges-
terone acetate has, with modem response criteria, been modified
and is now established at approximately 2% (Harris, 1983;
Linehan et al, 1989), and with no proven effect on survival. In the
present study, objective responses were observed including two
complete responses with tamoxifen-only treatment, and several
long-lasting remissions/stable diseases were also seen. Note that
these patients never received immuno- or chemotherapy.
Previously, tamoxifen in higher doses than used in this study has
also been shown to cause objective responses and even complete
responses in advanced RCC (Stahl et al, 1991). Nevertheless, even
if it cannot be established that tamoxifen has any clear-cut effects
on survival, tamoxifen because of its non-toxic features can be
used in the palliative setting. The role of endocrine manipulation
might at least be re-evaluated, especially in the context that
hormone treatment can interact with the immune system (Oliver,
1994). As a large number of objective responses and some long-
term survivors have been seen, even in this study over the years,
there might be a subpopulation ofpatients that could benefit from
immunotherapy (or hormone manipulation). Future studies are
therefore ofinterest to find methods to identify those patients.
In summary, even ifthe number ofpatients is relatively limited,
the present study questions the benefit ofimmunotherapy with IL-
2 andIFN-a as a routine treatment in the management ofadvanced
RCC. The study suggests the use of a less toxic regimen, for
example tamoxifen, in the routine setting and as an adequate
control in further trials. This assumption is also strengthened by
the difference in costs between the two treatment arms (drug costs
only: IL-2/IFN-a $27 000 vs $360 per patient in the tamoxifen-
only group). However, the chemoimmunotherapy approach with
and without 13-cis-retinoic acid (Motzer et al, 1995; Hanninen et
al, 1996; Atzpodien et al, 1997) is exciting and suggests that unex-
pected regimens might exist that are betterthan any thus fartested.
It is obvious that there is much need for investigation to find 'the
optimal' application for immunotherapy in the clinical setting.
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